Whole cell panning;Identify Tuberous Sclerosis Markers

全细胞淘选；识别结节性硬化症标志物

• 批准号: 6915258
• 负责人: MICHAEL P WEINER
• 金额: $ 12.38万
• 依托单位: ROTHBERG INSTITUTE, INC.
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-04-01 至 2007-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6915258
• 关键词: adipocytes; bacteriophage M13; biological signal transduction; biomarker; cell line; cell sorting; connective tissue neoplasm; immunocytochemistry; monoclonal antibody; polymerase chain reaction; posttranslational modifications; proteomics; tuberous sclerosis

DESCRIPTION (provided by applicant): We describe the development of human renal angiomyolipoma (AML) cell lines with which to provide an in vitro cellular model for use in identifying molecular markers of Tuberous Sclerosis Complex (TSC). Specifically, one goal of this proposal is to immortalize human AML cells and generate a set of matching TSC gene knock-in control cell lines. We shall use these cell-line reagents for whole cell biopanning using a naive bacteriophage M13 antibody library. AML specific markers will be validated using TSC-affected, and normal tissue samples. This proposal will form the foundation to a series of studies to identify cell markers that result from the inactivation of either the TSC1 or TSC2 genes. The current therapy for TSC is surgery to remove the lesions that result as a consequence of the disease. This option is not available for some clinical manifestations. The ultimate goal of our studies will be to derive a human monoclonal antibody for the immunotherapeutic treatment of TSC that can be used for all TSC patients.

描述(申请人提供)：我们描述了人肾血管肌脂肪瘤(AML)细胞系的发展，用它来提供一个体外细胞模型，用于鉴定结节性硬化症(TSC)的分子标志物。具体地说，这项提议的一个目标是使人类AML细胞永生化，并产生一套匹配的TSC基因敲入控制细胞系。我们将使用这些细胞系试剂，使用天然噬菌体M13抗体库进行全细胞生物扫描。AML特异性标志物将使用受TSC影响的组织样本和正常组织样本进行验证。这一提议将为一系列研究奠定基础，以确定TSC1或TSC2基因失活所导致的细胞标记。目前对TSC的治疗方法是手术切除由该疾病引起的病变。此选项不适用于某些临床表现。我们研究的最终目标将是获得一种可用于所有TSC患者的人源性单抗，用于TSC的免疫治疗。